CytoDyn (CYDY) Work In Process (2021 - 2022)

CytoDyn's (CYDY) quarterly Work In Process came in at $63.2 million in Q1 2022, down 4.35% on a QoQ basis from $66.0 million in Q4 2021.

CytoDyn (CYDY) Work In Process (2021 - 2022) Analysis & Trends

CytoDyn (CYDY) has 2 years of Work In Process data on file, last reported at $63.2 million in Q1 2022.

Quarterly Work In Process changed N/A year-over-year to $63.2 million in Q1 2022, while the trailing twelve-month figure through Feb 2022 was $63.2 million (changed N/A YoY) and the FY2021 annual result came in at $65.4 million, changed N/A from the prior year.
Work In Process retreated to $63.2 million in Q1 2022, from $66.0 million in the prior quarter.
In the past five years, Work In Process ranged from a high of $66.0 million in Q4 2021 to a low of $63.2 million in Q1 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	CytoDyn	258.01 Mn	258.01 Mn	-

Download Data